This is the basis for the synthetic lethality of PARP inhibitors (PARPis) in cancers with HR deficiency due to mutations in BRCA1/2 or other HR genes5, allowing these cancer cells to be selectively targeted while sparing normal cells that have intact DNA repair systems6. Here, BRCA1 is linked to cancer.